These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 38991984)

  • 1. Identification of mechanisms modulating chlorhexidine and octenidine susceptibility in Proteus mirabilis.
    Pelling H; Bennett V; Bock LJ; Wand ME; Denham EL; MacFarlane WM; Sutton JM; Jones BV
    J Appl Microbiol; 2024 Jul; 135(7):. PubMed ID: 38991984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. De-repression of the
    Pelling H; Bock LJ; Nzakizwanayo J; Wand ME; Denham EL; MacFarlane WM; Sutton JM; Jones BV
    Antimicrob Agents Chemother; 2019 Sep; 63(12):. PubMed ID: 31570392
    [No Abstract]   [Full Text] [Related]  

  • 3. Anti-Biofilm Effect of Octenidine and Polyhexanide on Uropathogenic Biofilm-Producing Bacteria.
    Loose M; Naber KG; Purcell L; Wirth MP; Wagenlehner FME
    Urol Int; 2021; 105(3-4):278-284. PubMed ID: 33401282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of Biofilm Forming Capability and Antibiotic Resistance in
    Egbule OS; Konye OP; Iweriebor BC
    Pak J Biol Sci; 2024 Apr; 27(5):268-275. PubMed ID: 38840467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipopolysaccharide structure modulates cationic biocide susceptibility and crystalline biofilm formation in
    Clarke OE; Pelling H; Bennett V; Matsumoto T; Gregory GE; Nzakizwanayo J; Slate AJ; Preston A; Laabei M; Bock LJ; Wand ME; Ikebukuro K; Gebhard S; Sutton JM; Jones BV
    Front Microbiol; 2023; 14():1150625. PubMed ID: 37089543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SmvA is an important efflux pump for cationic biocides in Klebsiella pneumoniae and other Enterobacteriaceae.
    Wand ME; Jamshidi S; Bock LJ; Rahman KM; Sutton JM
    Sci Rep; 2019 Feb; 9(1):1344. PubMed ID: 30718598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Exposure to Octenidine in a Simulated Sink Trap Environment Results in Selection of Pseudomonas aeruginosa,
    Garratt I; Aranega-Bou P; Sutton JM; Moore G; Wand ME
    Appl Environ Microbiol; 2021 Apr; 87(10):. PubMed ID: 33674437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased Usage of Antiseptics Is Associated with Reduced Susceptibility in Clinical Isolates of
    Hardy K; Sunnucks K; Gil H; Shabir S; Trampari E; Hawkey P; Webber M
    mBio; 2018 May; 9(3):. PubMed ID: 29844113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluoxetine and thioridazine inhibit efflux and attenuate crystalline biofilm formation by Proteus mirabilis.
    Nzakizwanayo J; Scavone P; Jamshidi S; Hawthorne JA; Pelling H; Dedi C; Salvage JP; Hind CK; Guppy FM; Barnes LM; Patel BA; Rahman KM; Sutton MJ; Jones BV
    Sci Rep; 2017 Sep; 7(1):12222. PubMed ID: 28939900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Catalase Activity is Critical for Proteus mirabilis Biofilm Development, Extracellular Polymeric Substance Composition, and Dissemination during Catheter-Associated Urinary Tract Infection.
    White AN; Learman BS; Brauer AL; Armbruster CE
    Infect Immun; 2021 Sep; 89(10):e0017721. PubMed ID: 34280035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Proteus mirabilis isolated from urine, resistance to antibiotics and biofilm formation].
    Cernohorská L; Chvílová E
    Klin Mikrobiol Infekc Lek; 2011 Jun; 17(3):81-5. PubMed ID: 21780025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced Susceptibility of Proteus mirabilis to triclosan.
    Stickler DJ; Jones GL
    Antimicrob Agents Chemother; 2008 Mar; 52(3):991-4. PubMed ID: 18180352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Copper affects virulence and diverse phenotypes of uropathogenic Proteus mirabilis.
    Huang WS; Lee YJ; Wang L; Chen HH; Chao YJ; Cheng V; Liaw SJ
    J Microbiol Immunol Infect; 2024 Jun; 57(3):385-395. PubMed ID: 38453541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteus mirabilis pmrI, an RppA-regulated gene necessary for polymyxin B resistance, biofilm formation, and urothelial cell invasion.
    Jiang SS; Liu MC; Teng LJ; Wang WB; Hsueh PR; Liaw SJ
    Antimicrob Agents Chemother; 2010 Apr; 54(4):1564-71. PubMed ID: 20123999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An investigation of the impact of triclosan adaptation on Proteus mirabilis clinical isolates from an Egyptian university hospital.
    Elekhnawy E; Sonbol F; Abdelaziz A; Elbanna T
    Braz J Microbiol; 2021 Jun; 52(2):927-937. PubMed ID: 33826115
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Pawar S; Ashraf MI; Mujawar S; Mishra R; Lahiri C
    Front Cell Infect Microbiol; 2018; 8():269. PubMed ID: 30131943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of Urease Enzyme Production and some Other Virulence Factors Expression in Proteus mirabilis by N-Acetyl Cysteine and Dipropyl Disulphide.
    Abdel-Baky RM; Ali MA; Abuo-Rahma GEAA; AbdelAziz N
    Adv Exp Med Biol; 2017; 973():99-113. PubMed ID: 28190143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial activities against biofilm formed by Proteus mirabilis isolates from wound and urinary tract infections.
    Wasfi R; Abd El-Rahman OA; Mansour LE; Hanora AS; Hashem AM; Ashour MS
    Indian J Med Microbiol; 2012; 30(1):76-80. PubMed ID: 22361765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contribution of the efflux pump AcrAB-TolC to the tolerance of chlorhexidine and other biocides in
    Wand ME; Darby EM; Blair JMA; Sutton JM
    J Med Microbiol; 2022 Mar; 71(3):. PubMed ID: 35324422
    [No Abstract]   [Full Text] [Related]  

  • 20. Role of type II topoisomerase mutations and AcrAB efflux pump in fluoroquinolone-resistant clinical isolates of Proteus mirabilis.
    Saito R; Sato K; Kumita W; Inami N; Nishiyama H; Okamura N; Moriya K; Koike K
    J Antimicrob Chemother; 2006 Sep; 58(3):673-7. PubMed ID: 16870650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.